Amerikanische Gesellschaft für Hirudotherapie

State Company for Marketing Drugs and Medical Appliances — KIMADIA

KIMADIA · Iraq · middle east

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Iraq's KIMADIA (State Company for Marketing Drugs and Medical Appliances) — the principal national entity for procurement, registration and oversight of medicines and medical devices; leech-specific regulatory pathway has not been independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
middle east
Country
Iraq
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Iraqi Drug Control Law (No. 40 of 1970 and its amendments)
  • Iraqi Ministry of Health regulations on medical devices and biomedical products

Prescriber Requirements

  • Iraqi Medical Association–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

KIMADIA and Ministry of Health registration as applicable; Arabic and English-language labelling. Standard cold-chain conditions; post-conflict reconstruction context may introduce logistical constraints.

Import/Export Rules

KIMADIA and Ministry of Health import authorisation; Ministry of Agriculture / veterinary services clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. The Kurdistan Region of Iraq operates parallel health structures under the Kurdistan Regional Government; ASH has not independently mapped how this affects live-organism medical device oversight.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.